| Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) (NCT06525675) | MedSIR | 2022-07-18 |
| A Study in Patients With Advanced Breast Cancer (NCT04942054) | Sun Pharma Advanced Research Company Limited | 2022-05-20 |
| A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer (NCT05275777) | National University Hospital, Singapore | 2022-05-19 |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer (NCT05029999) | University of Texas Southwestern Medical Center | 2022-04-20 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416) | Blueprint Medicines Corporation | 2022-04-07 |
| A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (NCT04985266) | Royal Marsden NHS Foundation Trust | 2022-03-30 |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (NCT05340413) | SOLTI Breast Cancer Research Group | 2022-03-25 |
| Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer (NCT05263882) | Fifth Affiliated Hospital, Sun Yat-Sen University | 2022-03-01 |
| D4 Choline Breast PET/CT (NCT04276272) | Imperial College London | 2022-02-24 |
| Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer (NCT05150652) | Irada Ibrahim-zada | 2022-02-18 |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (NCT05216432) | Relay Therapeutics, Inc. | 2021-12-08 |
| Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy (NCT04848454) | Peking University First Hospital | 2021-11-20 |
| ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (NCT06570031) | Ono Pharmaceutical Co., Ltd. | 2021-11-09 |
| Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) (NCT04738292) | University of Wisconsin, Madison | 2021-10-05 |
| Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer (NCT05173103) | University of Milano Bicocca | 2021-09-24 |
| A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer (NCT05054374) | Memorial Sloan Kettering Cancer Center | 2021-09-14 |
| Biology Guided Therapy for Breast Cancer for ER Positive (NCT04965688) | Inova Health Care Services | 2021-08-08 |
| Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer (NCT04573231) | University of Wisconsin, Madison | 2021-05-24 |
| Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors (NCT04764084) | Peking University Cancer Hospital & Institute | 2021-04-01 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959) | TransThera Sciences (Nanjing), Inc. | 2021-03-14 |
| Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer (NCT04624711) | The First Affiliated Hospital with Nanjing Medical University | 2021-03-01 |
| Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer (NCT05305924) | The Methodist Hospital Research Institute | 2021-02-25 |
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer (NCT04762979) | Marina N Sharifi | 2021-02-12 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (NCT04551495) | Jules Bordet Institute | 2021-01-14 |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (NCT04150042) | General Oncology, Inc. | 2021-01-13 |
| A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (NCT04588298) | AstraZeneca | 2020-11-02 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (NCT04595565) | GBG Forschungs GmbH | 2020-10-28 |
| Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (NCT04504331) | Jennifer Lee Caswell-Jin | 2020-10-13 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-10-07 |
| Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer (NCT04576143) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2020-09-20 |
| Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer (NCT04498793) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-09-01 |
| To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer (NCT04660435) | Fondazione Sandro Pitigliani | 2020-09-01 |
| A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer (NCT04505826) | Olema Pharmaceuticals, Inc. | 2020-08-13 |
| AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer (NCT04499118) | Sichuan Provincial People's Hospital | 2020-08-01 |
| Sacituzumab Govitecan In TNBC (NCT04230109) | Massachusetts General Hospital | 2020-07-14 |
| Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation (NCT03989089) | University of Malaya | 2020-07-03 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| A Phase 1 Study of [225Ac]-FPI-1434 Injection (NCT03746431) | Fusion Pharmaceuticals Inc. | 2019-01-17 |
| Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China (NCT03575065) | BeiGene | 2018-06-22 |
| Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (NCT03412643) | NSABP Foundation Inc | 2018-05-14 |
| Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging (NCT03568448) | New Mexico Cancer Research Alliance | 2018-04-16 |
| A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (NCT03251378) | Hutchison Medipharma Limited | 2017-12-11 |
| Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer (NCT03294694) | Dana-Farber Cancer Institute | 2017-11-08 |
| Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (NCT02315196) | Rutgers, The State University of New Jersey | 2015-02-25 |
| Phase II Study of Everolimus Beyond Progression (NCT02269670) | Emory University | 2014-11-25 |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer (NCT02273752) | Emory University | 2014-11-01 |
| Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus (NCT02015559) | Jonsson Comprehensive Cancer Center | 2014-10-08 |
| Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. (NCT02371174) | Eisai Co., Ltd. | 2014-09-03 |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer (NCT01938833) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-04-01 |
| Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery (NCT01953588) | Alliance for Clinical Trials in Oncology | 2014-02-27 |
| Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (NCT02225470) | Eisai Co., Ltd. | 2013-09-26 |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (NCT01881230) | Celgene | 2013-09-26 |
| Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer (NCT01818063) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2013-04-25 |
| BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (NCT01791478) | Vanderbilt-Ingram Cancer Center | 2013-04-01 |
| Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer (NCT01840306) | Cancer Trials Ireland | 2012-10-12 |
| Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer (NCT01705691) | NSABP Foundation Inc | 2012-09-01 |
| Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer (NCT01527487) | SCRI Development Innovations, LLC | 2012-06-01 |
| Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer (NCT01368263) | Washington University School of Medicine | 2011-09-01 |
| Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients (NCT01372579) | Northwestern University | 2011-08-01 |
| RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer (NCT01208441) | National Cancer Institute (NCI) | 2010-11-01 |
| Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery (NCT01234532) | University of Maryland, Baltimore | 2010-10-01 |
| Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer (NCT01104259) | University of Washington | 2010-07-01 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer (NCT01151449) | National Cancer Institute (NCI) | 2010-06-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (NCT01042379) | QuantumLeap Healthcare Collaborative | 2010-03-01 |
| Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer (NCT01100489) | Case Comprehensive Cancer Center | 2010-02-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer (NCT00679029) | University of Nebraska | 2008-05-02 |
| Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer (NCT00733408) | University of Washington | 2008-04-23 |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (NCT00618657) | University of California, Irvine | 2008-02-01 |
| Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer (NCT00194792) | University of Washington | 2005-08-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic (NCT00003440) | National Cancer Institute (NCI) | 1998-07-01 |